Helio Genomics Company Profile

Background

Helio Genomics, founded in 2016 and headquartered in Irvine, California, is an AI-driven biotechnology company specializing in diagnostics technology and test development for early cancer detection. The company's mission is to simplify cancer screening to save lives by detecting cancer earlier. Helio Genomics focuses on developing and advancing cutting-edge AI-enabled technologies to detect and screen cancer at its earliest stages, with a particular emphasis on liver, colon, breast, and lung cancers.

Key Strategic Focus

Helio Genomics' strategic focus centers on the development and commercialization of blood-based diagnostic technologies for early cancer detection. The company's flagship product, HelioLiver, is a multi-analyte blood test dedicated to the early detection of hepatocellular carcinoma (HCC), a common and aggressive form of liver cancer. By evaluating cell-free DNA (cfDNA) methylation patterns, serum protein markers, and demographic data, HelioLiver integrates AI and multi-marker analysis to deliver highly sensitive and specific diagnostic tools. The company's pipeline portfolio includes multi-cancer early detection (MCED) testing, focusing on cancers like liver, breast, and lung, which are notoriously challenging to detect early.

Financials and Funding

Specific financial details and funding history for Helio Genomics are not publicly disclosed. However, the company has demonstrated significant growth and strategic initiatives, such as the separation from its parent company, Laboratory for Advanced Medicine, Inc., in June 2024, to accelerate its strategic priorities as a standalone entity.

Pipeline Development

Helio Genomics' primary product, HelioLiver Dx, has undergone extensive clinical validation. The CLiMB trial, a multi-site, prospective study, demonstrated that HelioLiver Dx outperformed ultrasound in detecting HCC lesions in cirrhotic patients, particularly for lesions ≤ 4 cm. The test met prespecified coprimary and secondary endpoints, showcasing superior sensitivity and non-inferior specificity compared to ultrasound.

Technological Platform and Innovation

Helio Genomics leverages proprietary technologies and scientific methodologies to enhance early cancer detection:

ECLIPSE™ Platform: A proprietary laboratory process designed to improve the accuracy and efficiency of cfDNA methylation pattern detection and quantification. It optimizes each step of the cfDNA methylation capture process, including automated cfDNA extraction, library generation, enzymatic conversion, targeted capture, and next-generation sequencing (NGS).

MESA Approach: A flexible and sensitive method for capturing and integrating a diverse range of epigenetic features in cfDNA using a single experimental assay.

HelioLiver Test: A multi-analyte blood test that analyzes cfDNA methylation patterns, serum protein markers, and demographic information to detect early-stage HCC.

Leadership Team

Justin Chen Li: Chief Executive Officer. Under his leadership, Helio Genomics has focused on advancing AI-driven technologies for early cancer detection.

Gary Frazier: Chief Growth Officer. Appointed in February 2024, Frazier brings extensive experience in healthcare strategy, management, and technology. He is the founder and CEO of Worksite Labs and OM Healthcare and has held executive positions in healthcare systems management.

Dr. Richard Van Etten, MD, PhD: Chief Medical Advisor. Director of the Chao Family Comprehensive Cancer Center at UCI Health, specializing in the treatment of leukemia and other blood cancers.

Leadership Changes

In February 2024, Helio Genomics appointed Gary Frazier as Chief Growth Officer. Frazier's background includes founding and leading healthcare entities such as Worksite Labs and OM Healthcare, as well as serving as Vice President of Mergers and Acquisitions for Paladin Healthcare.

Competitor Profile

Market Insights and Dynamics

The global market for early cancer detection is experiencing significant growth, driven by advancements in biotechnology, increasing cancer prevalence, and the demand for non-invasive diagnostic methods. Blood-based tests, such as those developed by Helio Genomics, are gaining traction due to their convenience and potential for early detection.

Competitor Analysis

10x Genomics: An American biotechnology company that designs and manufactures gene sequencing technology used in scientific research. Founded in 2012, 10x Genomics focuses on advanced testing equipment for cellular biology.

Nebula Genomics: A personal genomics company offering whole-genome sequencing services. Founded in 2018, Nebula Genomics emphasizes privacy-preserving analysis of genomic datasets.

Strategic Collaborations and Partnerships

Halub Medical Co.: In October 2024, Helio Genomics announced a strategic partnership with Halub Medical Co. to commercialize HelioLiver Dx in Saudi Arabia and the Gulf Cooperation Council (GCC) region. The test is expected to be commercially available in Q1 2025, with anticipated revenue exceeding $10 million in the following 12 months.

Ochsner Health: Collaborated on a study demonstrating the utility of cfDNA methylation-based biomarkers for assessing biological aggressiveness and prognosis in patients with HCC. The study was presented at the 2024 San Antonio Liver Cancer Symposium and awarded as one of the top three abstracts.

Operational Insights

Helio Genomics' strategic initiatives, such as the separation from its parent company and the appointment of key executives, position it to effectively compete in the early cancer detection market. The company's focus on AI-driven, blood-based diagnostic technologies offers a distinct competitive advantage, addressing the need for non-invasive, accurate, and accessible cancer screening methods.

Strategic Opportunities and Future Directions

Helio Genomics is poised to expand its market presence through:

Regulatory Approvals: Pursuing FDA approval for HelioLiver Dx as a Class III medical device, with a PMA application submitted in Q2 2024.

Product Pipeline Expansion: Developing multi-cancer early detection tests targeting cancers such as breast and lung, leveraging its proprietary technologies and AI capabilities.

Global Market Penetration: Strengthening strategic partnerships, like the collaboration with Halub Medical Co., to commercialize products in international markets.